Phase I clinical data of APIM’s lead compound ATX-101 will be presented at the 2021 ASCO Annual Meeting. The poster with the title: “A first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA), shows a favorable safety profile and disease stabilization in late stage, heavily pre-treated, solid tumor patients” (abstract 3067), will be presented by Dr. Charlotte Lemech at the poster session “Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology” on June 4 starting at 3:00 pm.
